Arvinas goes public to bring its PROTAC-based anticancer drug to the market looking at an $100 mn IPO

On August 30th Arvinas, a preclinical biotech that is developing […]
read more »On August 30th Arvinas, a preclinical biotech that is developing […]
read more »